Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Family Health History PHGKB

Specific PHGKB|Family Health History PHGKB|Public Health Genomics and Precision Health Knowledge Base (PHGKB)

Last Posted: Apr 18, 2024
spot light Spotlight

Research biobank participants attitudes towards genetic exceptionalism and health record confidentiality.
Victoria Dortenzio et al. J Community Genet 2024 3 (Posted Apr 08, 2024 9AM)

From the abstract: "The goals of this study were to determine biobank participants’ attitudes towards genetic exceptionalism and confidentiality and whether those attitudes are related to their preference for return of genetic results. An online questionnaire was distributed to patients with an EHR and email address who had previously enrolled in the BioMe Biobank program. Most participants responded with similar levels of concern in scenarios involving the use of genetic information and other types of health information, suggesting that participants want similar protections for genetic data as other types of sensitive health information, particularly mental health and family history records. "

Susceptibility to Treatment-Resistant Depression Within Families.
Chih-Ming Cheng et al. JAMA Psychiatry 2024 4 (Posted Apr 05, 2024 9AM)

From the abstract: " Is the treatment-resistant depression (TRD) phenotype transmitted within a family? This cohort study found that, compared with control individuals match for birth year, sex, and kinship, first-degree-relatives of individuals with TRD had an increased risk of developing TRD and increased suicide mortality. The findings suggest that a family history of TRD might be a clinically significant risk factor for resistance to antidepressant treatment and increased suicide mortality, indicating that combining or altering therapies for depression might be considered instead of monotherapy at an earlier treatment stage. "

A call for increased inclusivity and global representation in pharmacogenetic testing.
April Kennedy et al. NPJ Genom Med 2024 2 (1) 13 (Posted Feb 23, 2024 3PM)

From the abstract: "Commercial pharmacogenetic testing panels capture a fraction of the genetic variation underlying medication metabolism and predisposition to adverse reactions. In this study we compared variation in six pharmacogenes detected by whole genome sequencing (WGS) to a targeted commercial panel in a cohort of 308 individuals with family history of pediatric heart disease. In 1% of the cohort, WGS identified rare variants that altered the interpretation of metabolizer status and would thus prevent potential errors in gene-based dosing. "

Recent advances in polygenic scores: translation, equitability, methods and FAIR tools.
Ruidong Xiang et al. Genome Med 2024 2 (1) 33 (Posted Feb 22, 2024 11AM)

From the abstract: " We review the latest potential benefits of PGS in the clinic and challenges to implementation. PGS could augment risk stratification through combined use with traditional risk factors (demographics, disease-specific risk factors, family history, etc.), to support diagnostic pathways, to predict groups with therapeutic benefits, and to increase the efficiency of clinical trials. However, there exist challenges to maximizing the clinical utility of PGS, including FAIR (Findable, Accessible, Interoperable, and Reusable) use and standardized sharing of the genomic data needed to develop and recalculate PGS, the equitable performance of PGS across populations."


news Latest News and Publications
Accepting or declining preconception expanded carrier screening: An exploratory study with 407 couples. External Web Site Icon
Ariane J A G Van Tongerloo et al. J Genet Couns 2024
Clinical features of prostate cancer by polygenic risk score. External Web Site Icon
Christina Spears et al. Fam Cancer 2024
Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer. External Web Site Icon
Florian Rumpf et al. J Urol 2024 101097JU0000000000003927
Prevalence of elevated lipoprotein(a) in cardiac rehabilitation patients - results from a large-scale multicentre registry in Germany. External Web Site Icon
Christoph Altmann et al. Clin Res Cardiol 2024
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses. External Web Site Icon
Emil K Gustavsson et al. Lancet Neurol 2024
The Significance of Screening Family Members in Glaucoma: Opportunities and Challenges. External Web Site Icon
Siddharth Bhargava et al. J Glaucoma 2024
BRCA awareness and testing experience in the UK Jewish population: a qualitative study. External Web Site Icon
Katrina Sarig et al. J Med Genet 2024
The Health History of First-Degree Relatives' Dyslipidemia Can Affect Preferences and Intentions following the Return of Genomic Results for Monogenic Familial Hypercholesterolemia. External Web Site Icon
Tomoharu Tokutomi et al. Genes (Basel) 2024 15(3)
Assessing Students' Knowledge and Attitudes Regarding the Risks and Prevention of Consanguineous Marriage: A Cross-Sectional Online Survey. External Web Site Icon
Ammar Abdulrahman Jairoun et al. J Multidiscip Healthc 2024 171251-1263
Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations. External Web Site Icon
Nicole Ciffone et al. Am Heart J Plus 2024 38100350
Low Rates of Colorectal Cancer Screening in Our Patients' First-Degree Relatives: Are We Failing Them? External Web Site Icon
Anyelin Almanzar et al. Dis Colon Rectum 2024
Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review. External Web Site Icon
Sook Pin Goh et al. BMC Cancer 2024 24(1) 316
Improving newborn screening test performance for metachromatic leukodystrophy: Recommendation from a pre-pilot study that identified a late-infantile case for treatment. External Web Site Icon
Teresa H Y Wu et al. Mol Genet Metab 2024 142(1) 108349
Integration and usability of a digital cancer risk stratification tool to optimize identification of patients at risk for hereditary cancers: A pilot study. External Web Site Icon
Emily M Webster et al. Gynecol Oncol 2024 1831-6
Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre. External Web Site Icon
Xin Wang et al. Clin Genitourin Cancer 2024 102052
Research biobank participants attitudes towards genetic exceptionalism and health record confidentiality. External Web Site Icon
Victoria Dortenzio et al. J Community Genet 2024
The Role of Demographic and Clinical Factors in Germline Mutation Testing for Patients with Primary Hyperparathyroidism. External Web Site Icon
Patrick T Hangge et al. Ann Surg Oncol 2024
Young Women's Perspectives on Being Screened for Hereditary Breast and Ovarian Cancer Risk During Routine Primary Care. External Web Site Icon
Mady Head et al. Womens Health Issues 2024
Additional findings from the 100,000 Genomes Project: a qualitative study of recipient perspectives. External Web Site Icon
Joshua J Nolan et al. Genet Med 2024 101103
Lipoprotein(a) testing in lipid clinics across the UK: Results of a national survey. External Web Site Icon
Saleem Ansari et al. J Clin Lipidol 2024
The frequency of colorectal lesions in the first-degree relatives of patients with colorectal lesions among PERSIAN Guilan Cohort Study population (PGCS). External Web Site Icon
Somaieh Matin et al. BMC Gastroenterol 2024 24(1) 88
Efficacy of Community Health Worker-Delivered Family Health History-Based Breast Cancer Education and Services Among Chinese Americans. External Web Site Icon
Bertille Assoumou et al. J Cancer Educ 2024
Leading Risk Factors for Congenital Deafness in the Context of Universal Neonatal Screening: Our Observations in a Four-Year Retrospective Study. External Web Site Icon
Antoine Paul et al. Int J Neonatal Screen 2024 10(1)
Genetic Testing in Hypertrophic Cardiomyopathy. External Web Site Icon
Catherine G Ireland et al. Am J Cardiol 2024 212SS4-S13
Prediction of non-suicidal self-injury in adolescents at the family level using regression methods and machine learning. External Web Site Icon
Si Chen Zhou et al. J Affect Disord 2024 35267-75
Correlates of U.S. Adults Aged 50-75 Years Having Had a Colorectal Cancer Screening Test. External Web Site Icon
Aisha T Langford et al. AJPM Focus 2024 3(2) 100187
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations. External Web Site Icon
Nam H Nguyen et al. JCO Clin Cancer Inform 2024 8e2300167
Genetic testing for familial hypercholesterolemia. External Web Site Icon
Yiyi Zhang et al. Curr Opin Lipidol 2024
Comparison of Two Strategies for Hypercholesterolemia Detection through Point-of-Care Testing. External Web Site Icon
Héctor Eliud Arriaga-Cázares et al. Diagnostics (Basel) 2024 14(2)
Using implementation science to develop a familial hypercholesterolemia screening program in primary care: The CARE-FH study. External Web Site Icon
Laney K Jones et al. J Clin Lipidol 2024

More


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP